Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcytic anemia — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for microcytic anemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
ClpB family mitochondrial disaggregase (CLPB) — CLPB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 7XBK · 3.7 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
Microcytic anaemia is most commonly caused by iron deficiency, which may result from abnormal bleeding, rapid growth, or inadequate diet. Orally administered iron supplements are usually effective, and parenteral therapy is rarely needed. However, exact identification of the cause is important because inappropriate iron therapy may be useless or even dangerous. Thalassaemia minor and anaemia of chronic disease are other frequent causes.
A 2025 case report describes a 65-year-old man with multiple comorbidities including hypertension, chronic kidney disease, diabetes, rheumatoid arthritis, and MGUS, who presented with three years of progressive fatigue and microcytic anaemia. Over 2.5 years his haemoglobin oscillated between 7.4 and 11.5 g/dL. Iron studies showed low serum iron, transferrin saturation of 9.6%, low UIBC, and elevated ferritin above 800 ng/mL, consistent with anaemia of chronic disease or iron sequestration. He received 26 intravenous iron infusions without significant haemoglobin improvement. Renal function improved to eGFR above 90, reducing the likelihood of CKD-related anaemia. Vitamin deficiencies, thyroid dysfunction, and a positive Coombs’ test were ruled out. Upper GI endoscopy confirmed H. pylori, which was treated successfully; colonoscopy showed benign polyps. Bone marrow biopsy revealed normocellular marrow with increased storage iron, mild reticulin fibrosis, and non-diagnostic megakaryocytic atypia. Bronchoalveolar lavage showed haemosiderin-laden macrophages. Despite epoetin alfa initiation, haemoglobin response remained minimal. The authors concluded that inflammation-driven impaired iron utilisation and erythropoiesis likely explained the poor response to both IV iron and erythropoietin.
A 2011 case report describes a 29-year-old man with dyspnoea, fatigue, and severe microcytic anaemia despite three years of iron therapy. Blood transfusions raised haemoglobin only temporarily, and IV iron did not. Bone marrow showed sideroblastic anaemia. The anaemia resolved with pyridoxine (vitamin B6) treatment, but severe iron overload required multiple phlebotomies. The patient became asymptomatic on pyridoxine with a normal haemoglobin level.
What is still missing is a systematic trial of pyridoxine in patients with microcytic anaemia unresponsive to iron, particularly those with evidence of iron overload or sideroblastic changes on bone marrow. The 2025 case also underscores the absence of a clear diagnostic pathway for chronic microcytic anaemia in patients with multiple inflammatory comorbidities; no trial has tested whether targeting inflammation directly improves haemoglobin in such patients. Funding for a prospective study stratifying patients by bone marrow findings, ferritin level, and inflammatory markers would be needed to move beyond single-case observations.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractIron deficiency, by far the most common cause of microcytic anemia, may be traced to abnormal bleeding, rapid growth, or rarely, inadequate diet. A search for the source of abnormal bleeding is particularly important because it may lead to detection of an ulcer or cancer. Orally administered iron supplements usually are effective; parenteral therapy is rarely needed.
https://doi.org/10.1080/00325481.1977.11712226AbstractThis article on microcytic anemia is the first of several on laboratory investigation of anemia. Microcytic anemia, characterized by a mean corpuscular volume of less than 80 cu mu, is usually due to iron deficiency or chronic disease but may signify thalassemia minor. Exact identification of the cause is important, since inappropriate iron therapy may be useless or even dangerous.
https://doi.org/10.1080/00325481.1979.11715037AbstractAbstract Title: A Diagnostic Dead-End: Chronic Microcytic Anemia in a Medically Complex Patient Background: Anemia, defined as hemoglobin <13 g/dL in men, is a common condition with numerous etiologies, including nutritional deficiencies, chronic disease, blood loss, and hemolysis. While most cases have identifiable causes, the etiology of a few remains unknown. Such cases pose a diagnostic challenge, requiring a multidisciplinary and longitudinal approach. This report presents a patient with chronic microcytic anemia unresponsive to conventional treatment despite an extensive workup. Case Presentation: A 65-year-old African-American male with hypertension, stage 3a CKD, type 2 diabetes, rheumatoid arthritis(RA), monoclonal gammapathy of undetermined significance (MGUS), COPD, gout, and prior H. pylori infection presented with three years of progressive fatigue, lightheadedness, and poor appetite. Hemoglobin consistently oscillated between 7.4-11.5 g/dl over 2.5 years, with microcytic indices. Iron studies showed low serum iron, transferrin saturation (9.6%), low UIBC, and elevated ferritin (>800 ng/mL), indicating anemia of chronic disease or iron sequestration. The patient received 26 intravenous iron infusions without significant hemoglobin improvement. Renal function declined in 2024 (eGFR 47.1) but improved in 2025 (>90), reducing CKD-related anemia likelihood. Other potential causes, such as vitamin deficiencies, LDH abnormality, thyroid dysfunction, and a negative Coombs’ test, were ruled out. Upper GI endoscopy confirmed H. pylori, treated successfully; colonoscopy revealed benign polyps. CT chest and PET-CT showed mild mediastinal lymphadenopathy and splenomegaly; biopsy and bronchoalveolar washings were negative for malignancy. Bone marrow biopsy, the gold standard, revealed normocellular marrow with increased storage iron, mild reticulin fibrosis, and non-diagnostic megakaryocytic atypia. Flow cytometry was unremarkable. Bronchoalveolar lavage showed hemosiderin-laden macrophages. Serum electrophoresis revealed two M-spikes without MGUS progression. Methotrexate was discontinued due to RA remission. Despite epoetin alfa initiation, hemoglobin response remained minimal. Discussion: This case highlights the challenges of diagnosing chronic microcytic anemia in a patient with multiple comorbidities. Iron studies suggested functional iron deficiency in the context of inflammation from his chronic diseases. Despite successful H. pylori treatment, normalized renal function, and extensive hematologic and imaging workup, no unifying etiology was found. The presence of hemosiderin-laden macrophages and mild splenomegaly may reflect occult processes such as chronic pulmonary bleeding or altered iron handling. The patient’s limited response to IV iron and erythropoietin supports the role of inflammation-driven impaired iron utilization and erythropoiesis. Close monitoring remains essential, as subtle or evolving hematologic pathology cannot be fully excluded, and chronic methotrexate therapy may also contribute to anemia.
https://doi.org/10.48448/kg6z-mr24AbstractThe most common cause of microcytic anemia is iron deficiency. We report a 29 year old man with history of dyspnea, fatigue and severe microcytic anemia despite iron therapy for 3 years. Blood transfusions elevated the hemoglobin levels temporarily, but iv iron did not. Bone marrow showed sideroblastic anemia. The anemia resolved with pyridoxine treatment but severe iron overload necessitated multiple phlebotomies. Today the patient is asymptomatic on pyridoxine with a normal hemoglobin level.
https://doi.org/10.17992/lbl.2011.01.339Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
